Venlafaxine

Is venlafaxine safe?

It is an effective antidepressant that is safe for most adults who are monitored, but it has more trade-offs than the first-choice SSRIs. Venlafaxine, sold as Effexor XR in the US and Efexor XL in the UK, is a serotonin and noradrenaline reuptake inhibitor (SNRI) for depression, generalised anxiety, social anxiety and panic disorder. It was filled about 16.3 million times in the US in 2024.

Three things set it apart. Stopping it is harder than with most antidepressants. It raises blood pressure at higher doses. And overdoses are more often fatal than with SSRIs. We score it 59, below duloxetine (66) and sertraline (72). It is not addictive, and for many people who did not respond to an SSRI it is the medicine that works.

Venlafaxine withdrawal: why stopping is hard

Venlafaxine has a half-life of about 5 hours, and its active metabolite about 11 hours. Levels fall quickly after a missed dose, and some people feel it the same day. The Effexor XR label lists a long set of discontinuation symptoms: dizziness, shock-like electrical sensations, nausea, anxiety, confusion, nightmares, insomnia, sweating and flu-like feelings. They are more frequent at higher doses and after longer treatment, and serious cases have been reported.

A 2024 meta-analysis of 79 studies in the Lancet Psychiatry found that about 31% of people had at least one symptom after stopping an antidepressant, against 17% after stopping placebo. Venlafaxine and desvenlafaxine were among the drugs linked to more frequent symptoms, and among those linked to more severe ones.

What helps: never stop abruptly, and plan a gradual reduction with your prescriber over weeks or months. The capsules must be swallowed whole (or sprinkled on applesauce), so tapering needs lower-strength capsules.

Blood pressure and the heart

Unlike SSRIs, venlafaxine raises blood pressure in a dose-related way. Across the Effexor XR trials, 1.4% of patients had a rise in diastolic pressure of at least 15 mmHg to 105 or above, against 0.9% on placebo, and 1% had systolic pressure rise by 20 mmHg or more to 180 or above, against 0.3%. Some had sustained hypertension, and cases needing urgent treatment have been reported.

The label says to control high blood pressure first and check it regularly. People with heart disease or past strokes need extra care. The UK label also warns about QT prolongationQT prolongationA delay in the heart's electrical recovery between beats, seen on an ECG. Some medicines cause it, and in rare cases it leads to a serious heart rhythm problem.More in the glossary and ventricular arrhythmia, mostly in overdose or with other risk factors.

UK guidance was once stricter. In December 2004 NICE guidance limited venlafaxine to specialist prescribing with a baseline ECG. After an appeal by the maker, Wyeth, the MHRA said in May 2006 that it was a suitable second-line option after an SSRI and that non-specialists could prescribe it below 300 mg a day.

Overdose: the main difference from SSRIs

This is the largest gap with SSRIs. A study of suicides and hospital overdoses in England and Wales from 2000 to 2006 compared deaths with non-fatal overdoses:

The label lists seizures, coma, QT and QRS prolongation, ventricular tachycardia, serotonin syndromeSerotonin syndromeA reaction caused by too much serotonin in the body, usually from combining medicines that raise it. Symptoms range from shivering to high fever.More in the glossary and death after overdose. It also notes that people prescribed venlafaxine tend to carry more suicide risk factors, so part of the gap may reflect who gets it. Either way, both the US and UK labels advise prescribing the smallest practical supply. If someone at home is at risk of self-harm, ask about smaller packs.

Any overdose needs hospital assessment. In the US call Poison Help on 1-800-222-1222; in the UK call 111, or 999 if someone is drowsy, fitting or has palpitations.

Side effects and the boxed warning

In the Effexor XR trials across all uses, 12% stopped for side effects against 4% on placebo. The commonest were nausea (30% vs 12%), insomnia (18% vs 10%), dizziness (16% vs 10%), sleepiness (15% vs 8%), dry mouth (15% vs 5%) and sweating (11% vs 3%). Sexual side effects are common; in October 2026 the MHRA named venlafaxine among antidepressants whose UK leaflets will mention post-SSRI sexual dysfunction, in which symptoms can continue after stopping.

Like every antidepressant in the US, it carries a boxed warningBoxed warningThe strongest safety warning the US FDA puts on a medicine's label, printed inside a black border at the top.More in the glossary about suicidal thoughts and behaviour in people under 25. Watch closely in the first months and after dose changes. Other label risks include serotonin syndromeSerotonin syndromeA reaction caused by too much serotonin in the body, usually from combining medicines that raise it. Symptoms range from shivering to high fever.More in the glossary with tramadol, triptans, lithium, fentanyl or St John's wort, bleeding with aspirin, NSAIDs or warfarin, low sodium in older people, seizures and mania.

Who should be careful

Talk to your doctor or pharmacist before starting venlafaxine if you have high blood pressure, heart disease or a past stroke, epilepsy, bipolar disorder, glaucoma, kidney or liver disease (lower doses are needed), take blood thinners or any other serotonin drug, drink heavily, or are pregnant. A lower score is not a reason to stop a medicine that is working; changes should be planned with your prescriber.

How we scored it

Track record (92) is strong. Overdose marginOverdose marginHow far a normal dose is from a harmful one. A wide margin means an accidental extra dose is unlikely to cause serious harm.More in the glossary (50) is the clearest gap with SSRIs, and dependence (60) reflects its reputation as one of the hardest antidepressants to stop. Serious side effects (60) include the dose-related rise in blood pressure, and regulatory warnings (45) reflect the class boxed warningBoxed warningThe strongest safety warning the US FDA puts on a medicine's label, printed inside a black border at the top.More in the glossary and past UK restrictions.